Prognostic Value of SUVmax on 18f-Fluorodeoxyglucose PET/CT Scan in Patients With Malignant Pleural Mesothelioma

PLoS ONE - United States
doi 10.1371/journal.pone.0229299
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

18f-Fluorodeoxyglucose PET/CT and Dynamic Contrast-Enhanced MRI as Imaging Biomarkers in Malignant Pleural Mesothelioma

Nuclear Medicine Communications
MedicineNuclear MedicineRadiologyImaging
2018English

Prognostic Factors in Patients With Malignant Pleural Mesothelioma

International Journal of Biomedicine
2015English

Prognostic Value of 18F‑fluorodeoxyglucose PET Parameters and Inflammation in Patients With Nasopharyngeal Carcinoma

Oncology Letters
Cancer ResearchOncology
2017English

The Value of [18F]fluorodeoxyglucose-Pet/Ct in Oesophageal Cancer

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2011English

Loco-Regional Staging of Malignant Pleural Mesothelioma by Integrated 18f-FDG PET/MRI

European Journal of Radiology
MedicineNuclear MedicineRadiologyImaging
2019English

Prognostic Value of SUVmax and Metabolic Tumor Volume on 18f-FDG PET/CT in Early Stage Non-Small Cell Lung Cancer Patients Without LN Metastasis

Bio-Medical Materials and Engineering
MedicineBiomaterialsBiomedical Engineering
2014English

[18F]Fluoride and [18F]fluorodeoxyglucose PET/CT in Myositis Ossificans of the Forearm

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2011English

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Prognostic Values of Mid-Radiotherapy 18f-FDG PET/CT in Patients With Esophageal Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy